Michael T. Rudd - Concepedia

Author

Michael T. Rudd

United States Military Academy ORCID

Also Known As

M. Rudd, M. T. RUDD, M.T. Rudd, MICHAEL RUDD, Michael Rudd, Michael T Rudd, Michael T. Rudd, Michael T. Rudd, Rudd, M.

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

United States Military Academy Merck & Co., Inc., Rahway, NJ, USA (United States)Stanford University Purdue University West Lafayette IRBM Science Park

About

Michael T. Rudd is an author at United States Military Academy specializing in chemistry, organic chemistry, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	11	11	534
2	Medicine	11	11	1.1K
3	Natural Sciences	8	8	663
4	Health Sciences	1	1	47
5	Public Health	1	1	48

Michael T. Rudd

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants Vincenzo Summa, Steven W. Ludmerer, John A. McCauley, Antimicrobial Agents and Chemotherapy	2012	254
Structural basis for selectivity and diversity in angiotensin II receptors Haitao Zhang, Gye Won Han, A. Batyuk, Nature Molecular PhysiologySignal TransductionG Protein-coupled ReceptorMedicineFunctional Selectivity	2017	212
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor Steven J. Harper, John A. McCauley, Michael T. Rudd, ACS Medicinal Chemistry Letters ImmunologyMolecular BiologyPharmacotherapyAntiviral DrugMedicinal Chemistry	2012	201
Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor John A. McCauley, Charles McIntyre, Michael T. Rudd, Journal of Medicinal Chemistry ImmunologyAntiviral DrugMedicinal ChemistryViral HepatitisAntiviral Drug Development	2010	176
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease Nigel J. Liverton, Steven S. Carroll, Jillian DiMuzio, Antimicrobial Agents and Chemotherapy ImmunologyMolecular BiologyAntiviral DrugExcellent SelectivityViral Hepatitis	2009	141
Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease Nigel J. Liverton, M. Katharine Holloway, John A. McCauley, Journal of the American Chemical Society Molecular DockingMedicinal ChemistryInitial CompoundsAntiviral CompoundBiochemistry	2008	134
Ruthenium-Catalyzed Cycloisomerizations of Diynols Barry M. Trost, Michael T. Rudd Journal of the American Chemical Society	2005	125
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation Chuan Hong, Noel Byrne, Beata Zamlynny, Nature Communications	2021	116
Chemoselectivity of the Ruthenium-Catalyzed Hydrative Diyne Cyclization: Total Synthesis of (+)-Cylindricine C, D, and E Barry M. Trost, Michael T. Rudd Organic Letters Chemical EngineeringEngineeringHeterocyclicAlkene MetathesisTotal Synthesis	2003	113
A Mechanistic Dichotomy in Ruthenium-Catalyzed Propargyl Alcohol Reactivity: A Novel Hydrative Diyne Cyclization Barry M. Trost, Michael T. Rudd Journal of the American Chemical Society EngineeringHeterocyclicAlkene MetathesisMechanistic DichotomyPropargyl Alcohols	2003	74

Page 1